Sanofi Delivers 2016 Sales and Business EPS(1)Growth at CER(2)
|Q4 2016||Change||Change (CER)||2016||Change||Change (CER)|
|IFRS net sales reported||€8,867m||+3.3%||+3.4%||€33,821m||-0.7%||+1.2%|
|IFRS net income reported||€790m||+136.5%||€4,709m||+9.8%|
|IFRS EPS reported||€0.62||+138.5%||€3.66||+11.6%|
|Business net income(1)||€1,606m||-6.0%||-2.9%||€7,308m||-0.9%||+2.5%|
Following the announcement of exclusive negotiations with Boehringer Ingelheim and as per the IFRS 5 presentation requirement for discontinued operations, net income for Sanofi’s Animal Health business (Merial) was reported on a separate line (“Net income from the held for exchange Animal Health Business”) in the Consolidated Income Statement for 2016 and the prior year. In the first three quarters of 2016, Sanofi comments included Merial for every income statement line using the term “Aggregate”. Sanofi neither presents “Aggregate” figures nor reports Animal Health business as an operating segment in Q4 2016 and in 2016 as a result of the closing early in 2017 of the swap of the Animal Health/CHC business with Boehringer Ingelheim. 2016 net sales including Animal Health(3) were €36,529 million of which €9,466 million in the fourth quarter of 2016.
|All Global Business Units delivered positive sales performance in the fourth quarter of 2016
2016 sales supported by Specialty care and Vaccines
Solid financial results in 2016 despite launch investments, supported by cost savings
Sanofi progresses on its strategic priorities
2017 financial guidance
Sanofi fa parte del gruppo “Healthcare” all’interno del portafoglio Black Dog.
Ad oggi l’investimento in Sanofi ha restituito 6.1 euro che corrispondono ad un tasso di payback del 1.91%.
Il nuovo dividend yeld netto “on cost” si attesta al 2.05% e al 2.12% considerando i dividendi già incassati.
Ad oggi l’investimento in Sanofi corrisponde allo 0.6% dell’intero portafoglio.